DelveInsight’s “Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Diabetic Neuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/diabetic-neuropathy-market

Key Takeaways from the Diabetic Neuropathy Market Report

• In January 2026, Lexicon Pharmaceuticals completed its End-of-Phase 2 meeting with the US FDA for pilavapadin in Diabetic Peripheral Neuropathic Pain, with no objections to Phase III, which will involve two 12-week placebo-controlled studies of a 10 mg dose, with a change in average daily pain score as the primary endpoint.
• According to DelveInsight’s estimates, the US accounts for the highest prevalent cases in 2025 and is expected to increase at a significant CAGR by 2036.
• According to the International Diabetes Federation (IDF), more than 43 million adults in the United States are affected by diabetes, highlighting the substantial national disease burden and associated risk of long-term complications.
• According to secondary sources, diabetic neuropathy, a common complication of diabetes, affects more than 30% of individuals with the disease, as reported by the Survey Research Group of the Japan Physicians Association.
• The observed female predominance and earlier onset of Diabetic Neuropathy highlight the importance of gender-specific screening, early diagnosis, and timely intervention to prevent disease progression and long-term complications.
• According to secondary sources, approximately 32% of individuals with diabetes in Italy were reported to have diabetic neuropathy, highlighting a substantial burden of neurological complications.
• The leading Diabetic Neuropathic Pain Companies include Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, and others.
• Promising Diabetic Neuropathic Pain Therapies include Duloxetine, CNTX-6016, MEDI 7352, and others.

Stay ahead in the Diabetic Neuropathy Therapeutics Market with DelveInsight’s Strategic Report @ Diabetic Neuropathy Market Outlook

Diabetic Neuropathy Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases of Diabetes Mellitus
• Total Diagnosed Prevalent Cases of Diabetic Neuropathy
• Gender-specific Diagnosed Prevalent Cases of Diabetic Neuropathy
• Total Treated Cases of Diabetic Neuropathy

Download the report to understand which factors are driving Diabetic Neuropathy epidemiology trends @ Diabetic Neuropathy Prevalence

Diabetic Neuropathy Approved Therapies

• Capsaicin (QUTENZA): Grünenthal (Averitas Pharma)

QUTENZA, developed by Grünenthal (through its US subsidiary Averitas Pharma), is a high-concentration (8%) topical capsaicin patch designed for the treatment of neuropathic pain, including pain associated with Diabetic Neuropathy. Capsaicin, the active component derived from chili peppers, acts as a TRPV1 receptor agonist, leading to de-functionalization of nociceptive nerve fibers and long-lasting pain relief following a single localized application.

Diabetic Neuropathy Pipeline Analysis

• Suzetrigine (JOURNAVX): Vertex Pharmaceuticals

Suzetrigine, developed by Vertex Pharmaceuticals, is an oral, highly selective NaV1.8 inhibitor, targeting the voltage-gated sodium channel predominantly expressed in peripheral nociceptive neurons, reducing the initiation and transmission of pain signals without affecting central nervous system pathways. This targeted peripheral action aims to provide effective analgesia while minimizing CNS-related side effects commonly seen with traditional pain therapies.

• Pilavapadin (LX9211): Lexicon Pharmaceuticals

LX9211, developed by Lexicon, is an orally administered small molecule being developed for the treatment of diabetic peripheral neuropathy. Preclinical studies demonstrated that LX9211 effectively penetrates the central nervous system and reduces pain behavior in neuropathic models without affecting opioid pathways. Discovered in a drug discovery alliance between Lexicon Pharmaceuticals and Bristol-Myers Squibb, Lexicon holds exclusive rights to its development and commercialization.

Get In-Depth Knowledge on Diabetic Neuropathy Market Trends and Forecasts with DelveInsight @ Diabetic Neuropathy Treatment Market

Diabetic Neuropathy Market Outlook

The Diabetic Neuropathy market is undergoing a gradual transformation, shifting beyond traditional symptomatic management with generic analgesics and antidepressants toward more targeted, mechanism-based therapies. The emergence of novel agents such as selective sodium channel inhibitors (e.g., Nav1.8 inhibitors) and kinase inhibitors highlights a growing focus on addressing underlying pain signaling pathways rather than broad CNS modulation. Additionally, non-systemic approaches like high-concentration capsaicin patches reflect a trend toward localized treatment with improved safety and reduced systemic side effects, enhancing patient adherence and tolerability. These innovations validate a shift toward precision-driven pain management and are reshaping the competitive landscape.

Diabetic Neuropathy Treatment Landscape

The Diabetic Neuropathy treatment landscape is evolving in line with other chronic, high-burden pain conditions where unmet need remains substantial. The United States represents the largest market, driven by high diabetes prevalence, improved diagnosis rates, strong access to advanced therapies, and increasing emphasis on opioid-sparing treatment strategies, followed by Europe and Japan. Overall, the introduction of differentiated, non-opioid therapies, expansion of pipeline assets with novel mechanisms, improving diagnosis rates, and growing awareness of diabetes-related complications are expected to drive steady growth in the 7MM diabetic neuropathy market from 2022 to 2036, creating significant commercial opportunities for both marketed therapies and emerging pipeline candidates.

Scope of the Diabetic Neuropathy Market Report

• Coverage- 7MM
• Diabetic Neuropathic Pain Companies- Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix, and others.
• Diabetic Neuropathic Pain Therapies- Duloxetine, CNTX-6016, MEDI 7352, and others.
• Diabetic Neuropathy Market Dynamics: Diabetic Neuropathy Market Drivers and Barriers
• Diabetic Neuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight’s Comprehensive Diabetic Neuropathy Market Report @ Diabetic Neuropathy Market Drivers and Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Diabetic Neuropathy Market Overview at a Glance

4. Executive Summary of Diabetic Neuropathy

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Disease Background and Overview

8. Treatment and Management

9. Epidemiology and Patient Population of Diabetic Neuropathy in the 7MM

10. Patient Journey

11. Marketed Therapies

12. Emerging Therapies

13. Diabetic Neuropathy: 7MM Market Analysis

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-neuropathy-market